KEY ACTIVITIES & PRESS Rebecca Nunn 5/17/20 KEY ACTIVITIES & PRESS Rebecca Nunn 5/17/20 AquaLung Therapeutics Corp. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS… READ PRESS RELEASE 5.20.20 Read More KEY ACTIVITIES & PRESS Rebecca Nunn 4/7/20 KEY ACTIVITIES & PRESS Rebecca Nunn 4/7/20 Fight Against COVID 19 May Yield Solutions to ARDS READ PRESS RELEASE 4.7.20 Read More Newer Posts
KEY ACTIVITIES & PRESS Rebecca Nunn 5/17/20 KEY ACTIVITIES & PRESS Rebecca Nunn 5/17/20 AquaLung Therapeutics Corp. Receives NIH Approval to Advance to IND-Enabling Studies Via the STTR Fastrack Phase II Award for Development of A Novel Anti-Inflammatory Therapeutic Antibody for ARDS… READ PRESS RELEASE 5.20.20 Read More
KEY ACTIVITIES & PRESS Rebecca Nunn 4/7/20 KEY ACTIVITIES & PRESS Rebecca Nunn 4/7/20 Fight Against COVID 19 May Yield Solutions to ARDS READ PRESS RELEASE 4.7.20 Read More
